Riskpilot← Back to searchSign inGet full accessVETPHARMA AS
ASActiveOrg 959362920Dølasletta 3C, 3408 TranbyWholesale of pharmaceutical and medical goods · NACE 4646Est. 19903 employees
Revenue 2024
NOK 19,7M
+7% vs 2023
EBITDA margin
8.5%
-46% vs 2023
Equity ratio
89.1%
Financial strength
Net profit 2024
NOK 1,7M
-32% vs 2023
| Revenue | NOK 19,7M | +7% |
| EBITDA | NOK 1,7M | -46% |
| Net profit | NOK 1,7M | -32% |
| Total assets | NOK 25,9M | -9% |
| Equity | NOK 23,1M | +8% |
| Employees | 3 | — |
Legal name
VETPHARMA AS
Org number
959362920
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29. oktober 1990
Share capital
NOK 30 400
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Øyvind wilhelm akselsen
Address
Dølasletta 3C, 3408 Tranby
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 963 | 19 908 | 20 730 | 18 506 | 19 741 |
| Staff expenses | −0 | −128 | −1 121 | −1 245 | −2 866 |
| EBITDA | 2 849 | 6 184 | 4 822 | 3 130 | 1 684 |
| Depreciation & amort. | −0 | −236 | −260 | −257 | −257 |
| EBIT | 2 849 | 5 948 | 4 563 | 2 873 | 1 427 |
| Net financials | −200 | 218 | 5 301 | 445 | 675 |
| Profit before tax | 2 649 | 6 166 | 9 864 | 3 318 | 2 103 |
| Tax | 553 | 1 306 | 883 | 741 | 362 |
| Net profit | 2 096 | 4 860 | 8 981 | 2 577 | 1 740 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 22 506 | 24 855 | 31 272 | 28 545 | 25 932 |
| Equity | 17 985 | 18 345 | 20 876 | 21 353 | 23 093 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 521 | 6 511 | 10 396 | 7 192 | 2 838 |
| Total debt | 4 521 | 6 511 | 10 396 | 7 192 | 2 838 |
EBITDA margin
8.5%
This company
15.8%
Market median
-46% vs market
20202024
Equity ratio
89.1%
This company
38.2%
Market median
+133% vs market
20202024
Return on equity
7.5%
This company
18.4%
Market median
-59% vs market
20202024
Net profit margin
8.8%
This company
8.1%
Market median
+9% vs market
20202024
Asset turnover
0.76×
This company
1.12×
Market median
-32% vs market
20202024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2026 | |
| Former (1) | ||
| Chairman | 2002 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 25.33% | 25.33% | 2022 | |
| Individual | 24.67% | 24.67% | 2022 | |
| Individual | 24.67% | 24.67% | 2024 | |
| Individual | 24.67% | 24.67% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VETPHARMA AS 
R31 EIENDOM ASBoard members of VETPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steinar Akselsen | Chairman | 0 companies |
| Anne Kristine Ebba Akselsen | Board of Directors | 0 companies |